NCT04471415 - Study to Investigate DRP-104 in Adults With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2020

Primary Completion Date

March 28, 2023

Study Completion Date

March 28, 2023

Conditions

Advanced Solid TumorNon Small Cell Lung Cancer Metastatic

Interventions

DRUG

DRP-104

"DRP-104 administered intravenously over 1 hour, three times per week (TIW) (Monday, Wednesday, Friday) for 2 consecutive weeks, one week off~DRP-104 administered subcutaneously twice weekly (Monday/Thursday or Tuesday/Friday) every week OR thrice weekly (Monday, Wednesday, Friday) every week"

BIOLOGICAL

atezolizumab

atezolizumab administered intravenously over 1 hour at 1200 mg once every 3 weeks.

Trial Locations (22)

100

National Taiwan University Hospital, Taipei

112

Taipei Veterans General Hospital, Taipei

10016

NYU Langone, New York

21231

Johns Hopkins Kimmel Institute, Baltimore

22031

NEXT Oncology, Fairfax

27514

University of North Carolina, Chapel Hill

28041

University Hospital 12 de Octubre, Madrid

32827

Florida Cancer Specialist, Orlando

34747

AdventHealth Medical Group, Kissimmee

37203

Sarah Cannon Research Institute, Nashville

37232

Vanderbilt University Medical Center, Nashville

43210

Ohio State University Comprehensive Cancer Center, Columbus

50924

Centrum fur Integrieerte Onkologie, Cologne

60590

University Hospital Frankfurt, Frankfurt

85258

HonorHealth, Scottsdale

90095

UCLA, Los Angeles

97070

University Klinikum Wuerzburg, Würzburg

169610

National Cancer Center Singapore, Singapore

02215

Dana Farber Cancer Institute, Boston

10029-6574

Icahn School of Medicine at Mount Sinai, New York

01307

University Cancer Center NCT, Dresden

08035

Hospital University Vall d'Hebron, Barcelona